Antibody-dependent enhancement of Marburg virus infection.

Authors: Nakayama E Tomabechi D Matsuno K Kishida N Yoshida R Feldmann H Takada A
Address: Department of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Journal:

Publication:

abstract

BACKGROUND:

Marburg virus (MARV) and Ebola virus (EBOV) cause severe hemorrhagic fever in primates. Earlier studies demonstrated that antibodies to particular epitopes on the glycoprotein (GP) of EBOV enhanced virus infectivity in vitro.

METHODS:

To investigate this Antibody-dependent enhancement (ADE) in MARV infection, we produced mouse antisera and monoclonal antibodies (mAbs) to the GPs of MARV strains Angola and Musoke.

RESULTS:

The infectivity of vesicular stomatitis virus pseudotyped with Angola GP in K562 cells was significantly enhanced in the presence of Angola GP antisera, whereas only minimal ADE activity was seen with Musoke GP antisera. This difference correlated with the percentage of hybridoma clones producing infectivity-enhancing mAbs. Using mAbs to MARV GP, we identified 3 distinct ADE epitopes in the mucinlike region on Angola GP. Interestingly, some of these antibodies bound to both Angola and Musoke GPs but showed significantly higher ADE activity for strain Angola. ADE activity depended on epitopes in the mucinlike region and glycine at amino acid position 547, present in the Angola but absent in the Musoke GP.

CONCLUSIONS:

These results suggest a possible link between ADE and MARV pathogenicity and provide new insights into the mechanisms underlying ADE entry of filoviruses.

Related Articles
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.
J Virol. 2006
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.
Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Ströher U, Hensley LE, Grolla A, Fritz EA, Feldmann F, Feldmann H, Jones SM. J Virol. 2006 Oct; 80(19):9659-66.
Infectivity-enhancing antibodies to Ebola virus glycoprotein.
J Virol. 2001
Infectivity-enhancing antibodies to Ebola virus glycoprotein.
Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y. J Virol. 2001 Mar; 75(5):2324-30.
Different potential of C-type lectin-mediated entry between Marburg virus strains.
J Virol. 2010
Different potential of C-type lectin-mediated entry between Marburg virus strains.
Matsuno K, Kishida N, Usami K, Igarashi M, Yoshida R, Nakayama E, Shimojima M, Feldmann H, Irimura T, Kawaoka Y, et al. J Virol. 2010 May; 84(10):5140-7. Epub 2010 Mar 10.
Review The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis.
Arch Virol Suppl. 1999
Review The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis.
Feldmann H, Volchkov VE, Volchkova VA, Klenk HD. Arch Virol Suppl. 1999; 15:159-69.
Review Development of vaccines for Marburg hemorrhagic fever.
Expert Rev Vaccines. 2007
Review Development of vaccines for Marburg hemorrhagic fever.
Bausch DG, Geisbert TW. Expert Rev Vaccines. 2007 Feb; 6(1):57-74.
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of ebola hemorrhagic Fever.
PLoS One. 2012
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of ebola hemorrhagic Fever.
Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, et al. PLoS One. 2012; 7(4):e36192. Epub 2012 Apr 27.
Filovirus tropism: cellular molecules for viral entry.
Front Microbiol. 2012
Filovirus tropism: cellular molecules for viral entry.
Takada A. Front Microbiol. 2012; 3:34. Epub 2012 Feb 6.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.